Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06436183
Status:
RECRUITING
Last Update Posted:
2024-05-30
First Post:
2024-04-09
Brief Title:
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
Sponsor:
Apollo Therapeutics Ltd
Organization:
Apollo Therapeutics Ltd
Study Overview
Official Title:
A Phase 2a Multicenter Randomized Double-blind 16-week Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2a multicenter randomized double-blind placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD
Detailed Description:
This study contains two parts Parts 1 and Part 2
Part 1 Blinded Period
Eligible patients will be randomized in a 111 ratio to receive either camoteskimab dose 1 camoteskimab dose 2 or placebo
Part 2 Extension Period
In part 2 all participants will receive camoteskimab
Part 1 Blinded Period
Eligible patients will be randomized in a 111 ratio to receive either camoteskimab dose 1 camoteskimab dose 2 or placebo
Part 2 Extension Period
In part 2 all participants will receive camoteskimab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None